B
Brad H. Nelson
Researcher at University of British Columbia
Publications - 173
Citations - 15220
Brad H. Nelson is an academic researcher from University of British Columbia. The author has contributed to research in topics: Cancer & Immunotherapy. The author has an hindex of 55, co-authored 152 publications receiving 12422 citations. Previous affiliations of Brad H. Nelson include Washington University in St. Louis & University of Victoria.
Papers
More filters
Journal ArticleDOI
Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer
David D.L. Bowtell,David D.L. Bowtell,Steffen Böhm,Ahmed Ashour Ahmed,Paul Joseph Aspuria,Robert C. Bast,Valerie Beral,Jonathan S. Berek,Michael J. Birrer,Sarah P. Blagden,Michael A. Bookman,James D. Brenton,Katherine B. Chiappinelli,Filipe C. Martins,George Coukos,Ronny Drapkin,Richard J. Edmondson,Christina Fotopoulou,Hani Gabra,Jérôme Galon,Charlie Gourley,Valerie Heong,David G. Huntsman,Marcin P. Iwanicki,Beth Y. Karlan,Allyson Kaye,Ernst Lengyel,Douglas A. Levine,Karen H. Lu,Iain A. McNeish,Usha Menon,Steven A. Narod,Brad H. Nelson,Kenneth P. Nephew,Paul D.P. Pharoah,Daniel J. Powell,Pilar Ramos,Iris L. Romero,Clare L. Scott,Anil K. Sood,Euan A. Stronach,Frances R. Balkwill +41 more
TL;DR: This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015 and aims to reduce incidence and improve outcomes for women with this disease.
Journal ArticleDOI
IL-2, Regulatory T Cells, and Tolerance
TL;DR: The discovery that IL-2 is critical for the development and peripheral expansion of CD4+CD25+ regulatory T cells, which promote self-tolerance by suppressing T cell responses in vivo, prompts a re-evaluation of how best to clinically manipulate this important immunoregulatory pathway.
Journal ArticleDOI
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown,Scott D. Brown,René L. Warren,Ewan A. Gibb,Ewan A. Gibb,Spencer D. Martin,Spencer D. Martin,John J. Spinelli,John J. Spinelli,Brad H. Nelson,Brad H. Nelson,Brad H. Nelson,Robert A. Holt,Robert A. Holt,Robert A. Holt +14 more
TL;DR: For 515 patients from six tumor sites, RNA-seq data from The Cancer Genome Atlas was used to identify mutations that were predicted to be immunogenic in that they yielded mutational epitopes presented by the MHC proteins encoded by each patient's autologous HLA-A alleles that were associated with increased patient survival.
Journal ArticleDOI
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry,Roberto Salgado,Thomas Gevaert,Prudence A. Russell,Prudence A. Russell,Thomas John,Thomas John,Bibhusal Thapa,Michael Christie,Koen Van de Vijver,Monica V. Estrada,Paula I. Gonzalez-Ericsson,Melinda E. Sanders,Benjamin Solomon,Cinzia Solinas,Gert Van den Eynden,Yves Allory,Yves Allory,Matthias Preusser,Johannes A. Hainfellner,Giancarlo Pruneri,Andrea Vingiani,Sandra Demaria,Fraser Symmans,Paolo Nuciforo,Laura Comerma,E. A. Thompson,Sunil R. Lakhani,Sunil R. Lakhani,Seong Rim Kim,Stuart J. Schnitt,Cecile Colpaert,Christos Sotiriou,Stefan J. Scherer,Michail Ignatiadis,Sunil S. Badve,Robert H. Pierce,Giuseppe Viale,Nicolas Sirtaine,Frédérique Penault-Llorca,Tomohagu Sugie,Susan Fineberg,Soonmyung Paik,Ashok Srinivasan,Andrea L. Richardson,Yihong Wang,Yihong Wang,Ewa Chmielik,Jane E. Brock,Douglas B. Johnson,Justin M. Balko,Stephan Wienert,Veerle Bossuyt,Stefan Michiels,Nils Ternès,Nicole Burchardi,Stephen J Luen,Stephen J Luen,Peter Savas,Peter Savas,Frederick Klauschen,Peter H. Watson,Peter H. Watson,Brad H. Nelson,Brad H. Nelson,Carmen Criscitiello,Sandra A O'Toole,Denis Larsimont,Roland de Wind,Giuseppe Curigliano,Fabrice Andre,Magali Lacroix-Triki,Mark van de Vijver,Federico Rojo,Giuseppe Floris,Shahinaz Bedri,Joseph A. Sparano,David L. Rimm,Torsten O. Nielsen,Zuzana Kos,Stephen M. Hewitt,Baljit Singh,Gelareh Farshid,Gelareh Farshid,Sibylle Loibl,Kimberly H. Allison,Nadine Tung,Sylvia Adams,Karen Willard-Gallo,Hugo M. Horlings,Leena Gandhi,Leena Gandhi,Andre L. Moreira,Fred R. Hirsch,Maria Vittoria Dieci,Maria Urbanowicz,Iva Brcic,Konstanty Korski,Fabien Gaire,Hartmut Koeppen,Amy C. Y. Lo,Amy C. Y. Lo,Jennifer M. Giltnane,Marlon Rebelatto,Keith Steele,Jiping Zha,Kenneth Emancipator,Jonathan Juco,Carsten Denkert,Jorge S. Reis-Filho,Sherene Loi,Stephen B. Fox +111 more
TL;DR: Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Book ChapterDOI
Biology of the interleukin-2 receptor.
TL;DR: In part because IL-2 was first identified as a T-cell growth factor, the major focus of investigation in IL-R2 signaling has been on the mechanism of mitogenic effects in cultured cell lines and the apparent functional redundancy of the A and H regions of IL- 2R beta, and their corresponding downstream pathways, with respect to the proliferative response.